Clinical trials · Michigan
Colorectal cancer clinical trials in Michigan
We’re tracking 74 recruiting colorectal cancer studies with a site in Michigan — including Phase 1, Phase 1/Phase 2, Phase 2, Phase 2/Phase 3 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in Michigan
- NCT07659795RecruitingPhase 2
Study of VS-7375 for KRAS G12D colorectal cancer
This trial tests a new targeted pill, VS-7375, for people with a specific type of advanced colorectal cancer called KRAS G12D. It's for those who either haven't had treatment yet or whose cancer has worsened after prior therapy.
Grand Rapids, MichiganAges 18 years+ - NCT05334069Recruiting
Blood test study for early cancer detection in patients
This study collects blood from people with cancer and people without cancer (or with possible cancer) to test whether new blood tests can detect cancer earlier. Your blood samples help researchers evaluate how well these tests work.
Alma, MichiganAges 40–75 - NCT07143487Recruiting
Family communication after genetic testing for colon cancer
This trial studies how patients with newly diagnosed colon cancer share genetic test results with their family members. It aims to improve communication and support after learning about hereditary risk.
Alma, MichiganAges 18 years+ - NCT06562192RecruitingPhase 1
Testing a radioactive drug for advanced pancreatic, lung, breast, and colorectal cancers
This trial tests a new radioactive drug (177Lu-NNS309) for people with advanced pancreatic, lung, breast, or colorectal cancer that has not responded to prior treatments. It aims to see if the drug can target and shrink tumors.
Grand Rapids, MichiganAges 18–100 - NCT07321106RecruitingPhase 1
CBI-1214 for advanced colorectal cancer
This trial tests a new drug called CBI-1214, which is designed to help your immune system attack cancer cells. It is for people with advanced colorectal cancer that has not responded to other treatments.
Grand Rapids, MichiganAges 18 years+ - NCT06974110RecruitingPhase 1
Study of a new drug for advanced solid tumors with MSI-H or dMMR
This trial tests an oral medication called MOMA-341 in people with advanced solid tumors that have high microsatellite instability (MSI-H) or mismatch repair deficiency (dMMR). It aims to see if the drug can help when prior immunotherapy hasn't worked or isn't available.
Detroit, MichiganAges 18 years+ - NCT07318805RecruitingPhase 1
A study of PF-08032562 for advanced solid tumors
This study tests a new medicine, PF-08032562, for people with advanced breast or colorectal cancer that has not responded to prior treatments. It aims to see if the drug is safe and can help shrink or slow the cancer.
Grand Rapids, MichiganAges 18 years+ - NCT03998202Recruiting
Study of chemotherapy side effects in older colorectal cancer patients
This study looks at how chemotherapy and immunotherapy affect the body in older adults with colorectal cancer, especially early side effects. It may help researchers understand why some people lose strength and how to better predict and manage treatment toxicity.
Brighton, MichiganAges 60 years+ - NCT04585750RecruitingPhase 1/Phase 2
Study drug for TP53 Y220C-mutated advanced cancers
This early-phase study tests PC14586 (rezatapopt) in people with advanced or metastatic solid cancers that carry a specific TP53 mutation called Y220C. It mainly looks at safety and how well the treatment may work, sometimes combined with pembrolizumab.
Detroit, MichiganAges 12 years+ - NCT05489211RecruitingPhase 2
Testing a cancer drug for advanced solid tumors
This Phase 2 study tests the drug Dato-DXd (alone or with other cancer medicines) in people with advanced solid tumors. It looks for tumor shrinkage and how safely the treatment can be given.
Grand Rapids, MichiganAges 18–130 - NCT06242470RecruitingPhase 1
Study of MGC026 for advanced solid tumors
This trial tests a new drug called MGC026 that targets a protein called B7-H3 on cancer cells, aiming to shrink or slow different advanced solid tumors. It is an early-phase study to find the right dose and check safety.
Grand Rapids, MichiganAges 18 years+ - NCT06695845RecruitingPhase 2
Study of zanidatamab for HER2-positive solid tumors
This trial tests a drug called zanidatamab in people with advanced solid tumors that have high levels of HER2 protein (called HER2-positive). It aims to see if zanidatamab can shrink or slow the growth of these tumors.
Detroit, MichiganAges 18 years+ - NCT07018869RecruitingPhase 3
A website to improve follow-up care for colorectal cancer survivors
This study tests if an educational website, viewed with a supporter, can improve follow-up care for people who had surgery for stage II or III colorectal cancer. It aims to help patients and their supporters find helpful information together.
Grand Rapids, MichiganAges 18 years+ - NCT07219238RecruitingPhase 2/Phase 3
PET scan for cancer spread in the abdomen
This trial tests a new PET/CT scan using a special tracer to detect cancer that has spread to the lining of the abdomen (peritoneal carcinomatosis) in people with colorectal, stomach, ovarian, or pancreatic cancer. It aims to see if this scan is better at finding the spread than standard imaging.
Grand Rapids, MichiganAges 18 years+ - NCT06820463RecruitingPhase 2
Study of telisotuzumab adizutecan plus chemo for metastatic colorectal cancer
This trial tests a new drug combination for people with metastatic colorectal cancer. The study includes an experimental antibody-drug conjugate (telisotuzumab adizutecan) plus standard chemotherapy and targeted therapies, to see if it works better than current options.
Ann Arbor, MichiganAges 18 years+ - NCT07284849RecruitingPhase 3
Testing a new drug combo for advanced colorectal cancer
This trial tests whether adding an experimental drug (INCA33890) to standard chemotherapy and bevacizumab helps people with a certain type of advanced colorectal cancer. It is for those whose cancer has spread and has not been treated yet with systemic therapy.
Ann Arbor, MichiganAges 18 years+ - NCT07228832RecruitingPhase 3
Study of two drugs with chemo for advanced colorectal cancer
This clinical trial tests a new drug, ivonescimab, against an approved drug, bevacizumab. Both are given with standard chemotherapy (FOLFOX) for people with advanced colorectal cancer that has not been treated yet with chemo or other drugs.
Detroit, MichiganAges 18 years+ - NCT06298916RecruitingPhase 1/Phase 2
Study of 64Cu-LNTH-1363S in Sarcoma or GI Cancer
This trial tests a new imaging agent, 64Cu-LNTH-1363S, to see if it can find certain sarcomas and gastrointestinal cancers. The goal is to help doctors better see where your cancer is and plan the best treatment. You may be eligible if you have a sarcoma or a GI cancer and are willing to have a tumor tissue sample taken.
Grand Rapids, MichiganAges 15 years+ - NCT07079631RecruitingPhase 1/Phase 2
Testing BNT314 with pumitamig and chemo for advanced colorectal cancer
This trial tests a new combination of drugs (BNT314 and pumitamig) plus chemotherapy for people with advanced colorectal cancer that has not responded to prior treatments. The goal is to see if this combination is safe and helps shrink or control the cancer.
Grand Rapids, MichiganAges 18 years+ - NCT06085560Enrolling by invitation
Choose and use an at-home colorectal cancer screening test
This study helps African American adults choose an at-home colorectal cancer screening test and make a plan to use it. It aims to make screening easier and more convenient for you.
Flint, MichiganAges 45–72 - NCT05673148RecruitingPhase 3
Ablation treatment plus usual therapy for limited metastatic bowel cancer
This study tests whether adding “total ablation” (carefully destroying all visible small tumors using surgery, heat/cold treatment, and/or targeted radiation) to standard chemotherapy improves outcomes for people with limited spread of colorectal cancer. It may help by aiming to eliminate all known metastatic spots while you continue usual cancer treatment.
Ann Arbor, MichiganAges 18 years+ - NCT04929223RecruitingPhase 1
Targeted drug study for metastatic colon or rectal cancer
This Phase 1 study tests targeted cancer treatments in people with metastatic colorectal cancer, using genetic “biomarker” results to match you to the right treatment group. It focuses first on safety, and also looks for early signs the treatment may work in specific tumor subgroups.
Detroit, MichiganAges 18 years+ - NCT05786924RecruitingPhase 1/Phase 2
Targeted cancer drug study for RAS/RAF mutation-positive tumors
This Phase 1/2 study tests S241656 (a targeted cancer medicine) in people whose cancers have certain “RAS/RAF” gene changes. It may help shrink tumors or control cancer growth, and also finds the safest dose and best way to use the drug.
Grand Rapids, MichiganAges 18 years+ - NCT05379595RecruitingPhase 1/Phase 2
Amivantamab for advanced colon or rectal cancer with specific tumor traits
This Phase 1/2 study tests amivantamab alone or combined with standard chemotherapy to treat advanced or metastatic colon or rectal cancer. You may be able to join if your tumor has the right genetic profile (typically “wild-type” for certain genes and no HER2 amplification) and your cancer has measurable or biopsy-able lesions.
Ann Arbor, MichiganAges 18 years+
Colorectal cancer trials by city in Michigan
Where these studies are running in Michigan
Institutions with a site for the recruiting colorectal cancer studies listed above.
- START Midwest · 7 studies
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor · 6 studies
- Henry Ford Health · 5 studies
- Hurley Medical Center · 5 studies
- Trinity Health IHA Medical Group Hematology Oncology - Brighton · 5 studies
- Trinity Health IHA Medical Group Hematology Oncology - Canton · 5 studies
- Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital · 5 studies
- Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus · 5 studies
What taking part in a colorectal cancer study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Colorectal cancer trials in other states
Common questions
- Are there colorectal cancer clinical trials in Michigan?
- Yes. We're currently tracking 74 recruiting colorectal cancer studies with a site in Michigan, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a colorectal cancer study in Michigan?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Michigan to take part?
- Not necessarily. These studies have a site in Michigan, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a colorectal cancer trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New colorectal cancer studies open in Michigan regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.